Becampanel

Becampanel

Becampanel

Chemical compound

Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM).[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.[1][2][3][5]

Quick Facts Clinical data, ATC code ...

References

  1. [1]
    Taylor JB, Triggle DJ (2007). Comprehensive medicinal chemistry II. Elsevier. p. 290. ISBN 978-0-08-044513-7.
  2. [2]
    Kwan P, Brodie MJ (September 2007). "Emerging drugs for epilepsy". Expert Opinion on Emerging Drugs. 12 (3): 407–422. doi:10.1517/14728214.12.3.407. PMID 17874969. S2CID 27627114.
  3. [3]
    Citraro R, Aiello R, Franco V, De Sarro G, Russo E (March 2014). "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy". Expert Opinion on Therapeutic Targets. 18 (3): 319–334. doi:10.1517/14728222.2014.874416. PMID 24387310. S2CID 1504490.
  4. [4]
    World Health Organization (1988). International Nonproprietary Names (INN) for Pharmaceutical Substances. W.H.O. ISBN 9789240560369.
  5. [5]
    Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK (September 2010). "Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices". Drug Discovery Today. 15 (17–18): 717–732. doi:10.1016/j.drudis.2010.06.014. PMID 20603226.


Stub icon

This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Becampanel, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.